Physician

Thanh Dinh Nguyen, M.D.

According to 2025 Medicare claims, Thanh Nguyen, M.D. (NPI: 1346419918) practices nephrology in the Merced, CA market, with the plurality of this provider's patient population coming from Merced, CA. This provider's primary affiliated billing organization is STANISLAUS KIDNEY AND HYPERTENSION (NPI: 1366767899; TIN: 272211798) and primary practice location at 95340-0964.

Nguyen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 651 traditional Medicare patients, billed 3,124 HCPCS/CPT codes, and received $307,400 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,380 prescription claims across 431 beneficiaries totaling $337,799 in drug costs, led by Jardiance (Empagliflozin). DME data shows 59 claims. Open Payments data shows 3 records totaling $80. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $431,379 to $307,400. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $626,178 to $337,799. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $2,287 to $1,263.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	795	4,447	$431,379
2016	840	4,565	$468,349
2017	845	4,488	$472,047
2018	869	3,966	$401,183
2019	805	3,699	$368,805
2020	686	2,868	$296,611
2021	663	2,997	$334,704
2022	669	3,236	$299,989
2023	626	3,474	$295,589
2024	651	3,124	$307,400

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	300	3,988	$626,178
2016	321	5,229	$879,958
2017	339	4,969	$929,373
2018	354	4,129	$490,081
2019	353	2,729	$287,887
2020	339	2,418	$347,799
2021	324	2,193	$333,868
2022	362	1,974	$318,806
2023	361	2,017	$321,399
2024	431	2,380	$337,799

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	20	$522
2016	N/R	14	$2,122
2017	N/R	11	$4,118
2018	N/R	51	$3,444
2019	N/R	57	$1,459
2020	N/R	170	$5,062
2021	N/R	83	$2,383
2022	N/R	103	$2,702
2023	N/R	114	$3,751
2024	N/R	59	$1,603

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	98	105	$133
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	115	200	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	369	664	$67
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	105	118	$62
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	184	658	$39

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	79	5,430	$92,255
Xphozah	Tenapanor Hcl	12	360	$35,002
Farxiga	Dapagliflozin Propanediol	40	1,920	$31,913
Sevelamer Carbonate	Sevelamer Carbonate	54	3,450	$29,021
Lokelma	Sodium Zirconium Cyclosilicate	26	1,059	$20,251

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7500	Azathioprine, oral, 50 mg	N	N/R	25	$1,051
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	21	$376
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$80	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Thanh Dinh Nguyen, M.D.?

Tedicare shows public-source Medicare data for Thanh Dinh Nguyen, M.D. (NPI 1346419918), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thanh Dinh Nguyen, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Thanh Dinh Nguyen, M.D.?

Thanh Dinh Nguyen, M.D. is linked to STANISLAUS KIDNEY AND HYPERTENSION (billing NPI 1366767899) in the available physician profile data.

Does Thanh Dinh Nguyen, M.D. have Open Payments data?

Thanh Dinh Nguyen, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.